Search with one or more keywords

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml
XML

Export to XML

Please choose the format :

XML
XML-DDI
pdf
PDF

Export to PDF

Which version do you want to export ?

Download full content
Download light content
csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection
Export to CSV

ARCHIVES : 309 forms

Sorting of results :

CESAME - Cancer and Increased Risk Associated with Inflammatory Bowel Disease in France

Head : Beaugerie Laurent, UMRS-S 707

Version 2
Voir
View
Overview

97

Last update : 12/01/2017

ARCHIVE

CESAME - Cancer and Increased Risk Associated with Inflammatory Bowel Disease in France

Head : Beaugerie Laurent, UMRS-S 707

Main objective

General objective: To test the hypothesis that the use of immunosuppressants (IS) for inflammatory bowel disease (IBD) leads to an increased risk of lymphoma in a cohort population. Secondary objective: to assess - relative risk associated with IS treatment for all cancers, to assess the standardised incidence rate for all other cancers observed during IBD; -The increased risk of colorectal cancer associated with extensive and former colonic inflammation for ulcerative colitis (UC) and Crohn's disease: - Increased risk of ileal adenocarcinoma associated with chronic ileal inflammation in Crohn's disease; - Evaluation of mortality of patients with IBD diseases and risk factors; - Protective role of salicylates, pregnancy and malformation syndromes.

Inclusion criteria

Subjects with IBD (Crohn's disease, ulcerative colitis, and indeterminate colitis) defined according to the usual diagnostic criteria, who attended consultation at least once between May 2005 and May 2006.

Last update : 12/01/2017

Voir
View

SIRS - Health, Inequalities and Social Ruptures

Head : Chauvin Pierre, UMRS 707, equipe ds3 - UPMC

Version 3
Voir
View
Overview

98

Last update : 01/01/2019

ARCHIVE

SIRS - Health, Inequalities and Social Ruptures

Head : Chauvin Pierre, UMRS 707, equipe ds3 - UPMC

Main objective

General objective: to investigate the impact of living conditions and social integration on health and health care usage. Secondary objective: to investigate territorial factors (social, urban and available services) in relation to health an health care usage.

Inclusion criteria

Voluntary French-speaking adults

Last update : 01/01/2019

Voir
View

TROPHEE - Benign prostatic hyperplasia: management and medical needs not covered in general practice in France

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1
Voir
View
Overview

99

Last update : 01/01/2020

ARCHIVE

TROPHEE - Benign prostatic hyperplasia: management and medical needs not covered in general practice in France

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

To describe the general practitioner long term management plan for patients with symptoms of BPH in France

Inclusion criteria

• Patients over 50 years old
• Patients with a diagnosis of BPH for at least 1 year
• Patients currently treated with at least one of the treatments for symptoms of BPH

Last update : 01/01/2020

Voir
View

SurvSein - Study on long-term iatrogenic effects for women treated for breast cancer between 1954 and 1985 at the Institut Gustave Roussy

Head : De Vathaire Florent, U1018 CESP équipe 3
Rubino Carole, U1018 CESP équipe 3

Version 2
Voir
View
Overview

100

Last update : 09/05/2017

ARCHIVE

SurvSein - Study on long-term iatrogenic effects for women treated for breast cancer between 1954 and 1985 at the Institut Gustave Roussy

Head : De Vathaire Florent, U1018 CESP équipe 3
Rubino Carole, U1018 CESP équipe 3

Main objective

SurvSein is a prospective and retrospective cohort study of women treated for breast cancer between 1954 and 1983 at the Institut Gustave Roussy in order to measure the iatrogenic effects of long-term treatment.

Inclusion criteria

Subjects of female gender Women aged 18 or over Women treated for breast cancer

Last update : 09/05/2017

Voir
View

DEFI - Determination of epidemiology of fibromyalgia

Head : Millet Véronique, Pfizer

Version 1
Voir
View
Overview

101

Last update : 01/01/2019

ARCHIVE

DEFI - Determination of epidemiology of fibromyalgia

Head : Millet Véronique, Pfizer

Main objective

Main:
- Evaluate the prevalence of fibromyalgia in the general population, in five ""French regions"", by identifying:
• in a first step, by telephone, potential or known fibromyalgia patients,
• then in a second step, from among these patients, those that have fibromyalgia validated by a rheumatologist.
Secondary:
- Describe the characteristics of the patients with a diagnosis of fibromyalgia validated by a rheumatologist.
- Describe the characteristics of patients for whom this diagnosis has not been validated by the rheumatologist.
- Compare the characteristics of these two groups of patients to one another and each of them with the characteristics of the general population of the study.

Inclusion criteria

- Patients aged 18 years or older.
- Patients deemed apt to answer the questions.
- Randomly selected patients who accept to participate in the survey (in the event of a refusal, the selected person was not replaced within the home or in the study)."

Last update : 01/01/2019

Voir
View

- Management of high cardiovascular risk patients treated with statins in France

Head : Piedbois Pascal
Thomas-Delecourt Florence, AstraZeneca

Version 4
Voir
View
Overview

102

Last update : 01/01/2019

ARCHIVE

- Management of high cardiovascular risk patients treated with statins in France

Head : Piedbois Pascal
Thomas-Delecourt Florence, AstraZeneca

Main objective

To describe utilisation of newly prescribed statins in French primary care

Inclusion criteria

Any patient for whom a treatment with statin was initiated for at least 3 months and less than 6 months

Last update : 01/01/2019

Voir
View

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here